Sionna Therapeutics Completes Phase 2a Enrollment, Expects Summer Topline and Holds $289.9M Cash
Sionna Therapeutics completed enrollment in its PreciSION CF Phase 2a proof-of-concept trial for NBD1 stabilizer SION-719 and expects topline data by summer 2026. The company reported a Q1 net loss of $26.8 million, raised R&D spending to $19.0 million, and holds $289.9 million in cash to fund operations through 2028.
1. Pipeline Progress and Timelines
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care, with topline data expected in summer 2026. A parallel Phase 1 dual combination trial of SION-451 with modulators SION-2222 and SION-109 remains on track for a summer 2026 readout.
2. Q1 Financial Performance
Research and development expenses rose to $19.0 million in the first quarter of 2026 from $13.7 million year-over-year, driven by advancement of the clinical pipeline and personnel costs. General and administrative expenses increased to $10.6 million from $6.0 million, contributing to a net loss of $26.8 million in Q1 2026 versus $16.5 million in Q1 2025.
3. Cash Position and Runway
As of March 31, 2026, the company held $289.9 million in cash, cash equivalents and marketable securities, providing a funding runway into 2028. This strong liquidity position underpins ongoing development of Sionna’s clinical-stage programs.